Antibiotic prophylaxis for patients with acute leukemia

References

• Bow E J. Infectious complications in patients receiving cytotoxic therapy for acute leukemia: history, background and approaches to management. Management of Infection in Oncology Patients, J R Wingard, R A Bowden. Martin Dunitz, London 2003; 71–104
   Google Scholar
• McQuay H J, Moore R A. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997; 126: 712–720
   PubMed Web of Science ®Google Scholar
• Hammond S P, Baden L R. Antibiotic prophylaxis during chemotherapy-induced neutropenia for patients with acute leukemia. Curr Hematol Malignancy Reports 2007; 2: 97–103
   PubMedGoogle Scholar
• DePauw B E, Donelly P J. Prophylaxis and aspergillosis—has the principle been proven?. N Engl J Med 2007; 356: 409–411
   PubMed Web of Science ®Google Scholar
• Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi M S, Martinelli G, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353: 977–987
   PubMed Web of Science ®Google Scholar
• Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 353: 988–998
   PubMed Web of Science ®Google Scholar
• Bodey G P, Buckley M, Sathe Y S, Freireich E J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328–340
   PubMed Web of Science ®Google Scholar
• Moran G J, Krishnadasan A, Gorwitz R J, Fosheim G E, McDougal L K, Carey R B, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355: 666–674
   PubMed Web of Science ®Google Scholar
• Glynn M K, Reddy V, Hutwagner L, Rabatsky-Ehr T, Shiferaw B, Vugia D J, et al. Prior antimicrobial agent use increases the risk of sporadic infections with multidrug-resistant Salmonella enterica serotype typhimurium: a FoodNet case-control study, 1996–1997. Clin Infect Dis 2004; 38: S227–S236
   PubMed Web of Science ®Google Scholar
• Richard P, Delangle M H, Raffi F, Espaze E, Richet H. Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora. Clin Infect Dis 2001; 32: 162–166
   PubMed Web of Science ®Google Scholar
• Bolon M K, Wright S B, Gold H S, Carmeli Y. The magnitude of the association between fluoroquinolone use and quinolone-resistant Escherichia coli and Klebsiella pneumoniae may be lower than previously reported. Antimicrob Agents Chemother 2004; 48: 1934–1940
   PubMed Web of Science ®Google Scholar
• Garau J, Xercavins M, Rodriguez-Carballeira M, Gomez-Vera J R, Coll I, Vidal D, et al. Emergence and dissemination of quinolone-resistant Eshcerichia coli in the community. Antimicrob Agents Chemother 1999; 43: 2736–2741
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Fishman N O, Bilker W B, Castiglioni A, Metlay J P, Edelstein P H, et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 2002; 162: 2469–2477
   PubMed Web of Science ®Google Scholar
• Pena C, Albareda J M, Pallares R, et al. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother 1995; 39: 520–524
   PubMed Web of Science ®Google Scholar
• Lo N, Cullen M. Antibiotic prophylaxis in chemotherapy-induced neutropenia: time to reconsider. Hematol Oncol 2006; 24: 120–125
   PubMed Web of Science ®Google Scholar
• Enno A, Darrell J, Hows J, Catovsky D, Goldman J M, Galton D AG. Co-trimoxazole for prevention of infection in acute leukaemia. Lancet 1978; 2: 395–397
   PubMed Web of Science ®Google Scholar
• Gualtieri R J, Donowitz G R, Kaiser D L, Hess C E, Sande M A. Double-blind randomized study of prophylactic trimethoprim-sulfamethoxazole in granulocytopenic patients with hematologic malignancies. Am J Med 1983; 74: 934–940
   PubMed Web of Science ®Google Scholar
• Weiser B, Lange M, Fialk M A, Singer C, Szatrowski T H, Armstrong D. Prophylactic trimethorprim-sulfamethoxazole during consolidation chemotherapy for acute leukemia: a controlled trial. Ann Intern Med 1981; 95: 436–438
   PubMed Web of Science ®Google Scholar
• Karp J E, Merz W G, Hendricksen C, Laughon B, Redden T, Bamberger B J, et al. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. Ann Intern Med 1987; 106: 1–7
   PubMed Web of Science ®Google Scholar
• Bow E J, Mandell L A, Louie T J, et al. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. Ann Intern Med 1996; 125: 183–190
   PubMed Web of Science ®Google Scholar
• The GIMEMA Infection Program. Prevention of bacterial infection in neutropenic patient with hematologic malignancies. Ann Intern Med 1991; 115: 7–12
   PubMed Web of Science ®Google Scholar
• International Antimicrobial Therapy Cooperative Group of the European Organization for Treatment of Cancer. Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. JAMA 1994; 272: 1183–1189
   PubMed Web of Science ®Google Scholar
• Talbot G H, Cassileth P A, Paradiso L, et al. Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. Antimicrob Agents Chemother 1993; 37: 474–482
   PubMed Web of Science ®Google Scholar
• Baden L R. Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 2005; 353: 1052–1054
   PubMed Web of Science ®Google Scholar
• Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996; 23: 795–805
   PubMed Web of Science ®Google Scholar
• Engels E A, Lau J, Barza M. Efficacy of quniolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16: 1179–1187
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database of Systematic Reviews 2005; 4: CD004386, DOI:10.1002/14651858.CD004386.pub2
   PubMedGoogle Scholar
• Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142: 979–995
   PubMed Web of Science ®Google Scholar
• Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A, et al. Antibiotic prophylaxis in neutropenic patients. Cancer 2006; 107: 1743–1751
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Seifert H, Wenzel R P, Edmond M B. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003; 36: 1103–1110
   PubMed Web of Science ®Google Scholar
• Zinner S H. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999; 29: 490–494
   PubMed Web of Science ®Google Scholar
• Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, et al. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis 1996; 15: 291–296
   PubMed Web of Science ®Google Scholar
• Bochud P Y, Eggiman P, Calandra T, Van Melle G, Saghafi L, Francioli. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994; 18: 25–31
   PubMed Web of Science ®Google Scholar
• Elting L S, Bodey G P, Keefe B H. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992; 14: 1201–1207
   PubMed Web of Science ®Google Scholar
• Tunkel A R, Sepkowitz K A. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis 2002; 34: 1524–1529
   PubMed Web of Science ®Google Scholar
• Kern W, Linzmeier K, Kurrle E. Antimicrobial susceptibility of viridans streptococci isolated from patients with acute leukemia receiving ofloxacin for antibacterial prophylaxis. Infection 1989; 17: 396–397
   PubMed Web of Science ®Google Scholar
• Timmers G J, Dijstelbloem, Simoons-Smit A M, van Winkelhoff A J, Touw D J, Vandenbroucke-Grauls, et al. Pharmacokinetics and effects on bowel and throat microflora of oral levofloxacin as antibacterial prophylaxis in neutropenic patients with haematological malignancies. Bone Marrow Transplant 2004; 33: 847–853
   PubMed Web of Science ®Google Scholar
• Razonable R R, Litzow M R, Khaliq Y, Piper K E, Rouse M S, Patel R. Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis 2002; 34: 1469–1474
   PubMed Web of Science ®Google Scholar
• Carratala J, Alcaide F, Fernandez-Sevilla A, Corbella X, Linares J, Gudiol F. Bacteremia due to viridians streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clin Infect Dis 1995; 20: 1169–1173
   PubMed Web of Science ®Google Scholar
• Gonzalez-Barca E, Carratala J, Mykietiuk A, Fernandez-Sevilla A, Gudiol F. Predisposing factors and outcome of Staphylococcus aureus bacteremia in neutropenic patients with cancer. Eur J Clin Microbiol Infect Dis 2001; 20: 117–119
   PubMed Web of Science ®Google Scholar
• Cometta A, Calandra T, Bille J, et al. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994; 330: 1240–1241
   PubMed Web of Science ®Google Scholar
• Oppenheim B A, Hartley J W, Lee W, Burnie J P. Outbreak of coagulase negative staphylococcus highly resistant to ciprofloxacin in a leukemia unit. Br Med J 1989; 299: 294–297
   PubMed Web of Science ®Google Scholar
• Kotilainen P, Nikoskelainen J, Huovinen P. Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients recieveing ciprofloxacin. J Infect Dis 1990; 161: 41–44
   PubMed Web of Science ®Google Scholar
• Loo V G, Poirier L, Miller M A, Oughton M, Libman M D, Michaud, et al. A predominately clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442–2449
   PubMed Web of Science ®Google Scholar
• von Baum H, Sigge A, Bommer M, Kern V W, Marre R, Dohner H, et al. Moxifloxacin prophylaxis in neutropenic patients. J Antimicrob Chemother 2006; 58: 891–894
   PubMed Web of Science ®Google Scholar
• Olsen S J, DeBess E E, McGivern T E, et al. A nosocomial outbreak of fluoroquinolone-resistant salmonella infection. N Engl J Med 2001; 344: 1572–1579
   PubMed Web of Science ®Google Scholar
• Ryan C A, Nickels M K, Hargrett-Bean N T, et al. Massive outbreak of antimicrobial-resistant salmonellosis traced to pasteurized milk. JAMA 1987; 258: 3269–3274
   PubMed Web of Science ®Google Scholar
• Kern W F, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergence of fluoroquinolone resistant Escherichia coli at a cancer center. Antimicrob Agent Chemother 1994; 38: 681–687
   PubMed Web of Science ®Google Scholar
• Carratala J, Fenandez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995; 20: 557–560
   PubMed Web of Science ®Google Scholar
• Kern W V, Steib-Bauert M, de With K, et al. Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999 – 2002. J Antimicrob Chemother 2005; 55: 57–60
   PubMed Web of Science ®Google Scholar
• Bucaneve G, Castagnola E, Viscoli C, Leibovici L, Menichetti F. Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients. Eur J Cancer Suppl 2007; 5: 5–12
   Web of Science ®Google Scholar
• Kern W V, Klose K, Jellen-Ritter A S, Oethinger M, Bohnert J, Kern P, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005; 24: 111–118
   PubMed Web of Science ®Google Scholar
• Gomez L, Garau J, Estrada C, Marquez M, Dalmau D, Xercavins M, et al. Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli. Cancer 2003; 97: 419–424
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Metlay J P, Bilker W B, Edelstein P H, Fishman N O. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis 2005; 41: 923–929
   PubMed Web of Science ®Google Scholar
• Oethinger M, Jellen-Ritter A S, Conrad S, Marre R, Kern W V. Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis. Infection 1998; 26: 379–384
   PubMed Web of Science ®Google Scholar
• Baden L R, Thiemke W, Skolnik A, et al. Prolonged colonization with vancomycin-resistant Enterococcus faecium in long-term care patients and the significance of “clearance.”. Clin Infect Dis 2001; 33: 1654–1660
   PubMed Web of Science ®Google Scholar
• Donskey C J, Chowdhry T K, Hecker M T, Hoyen C K, Hanrahan J A, Hujer A M, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000; 343: 1925–1932
   PubMed Web of Science ®Google Scholar
• Freifeld A, Marchigiani D, Walsh T, et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341: 305–311
   PubMed Web of Science ®Google Scholar
• Kern W V, Cometta A, de Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999; 341: 312–318
   PubMed Web of Science ®Google Scholar